Status:
COMPLETED
Phase 2/3 Study of ALK-001 in Geographic Atrophy
Lead Sponsor:
Alkeus Pharmaceuticals, Inc.
Conditions:
Geographic Atrophy
Age Related Macular Degeneration
Eligibility:
All Genders
60+ years
Phase:
PHASE2
PHASE3
Brief Summary
This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related...
Detailed Description
There is no oral treatment available for Geographic Atrophy secondary to AMD. AMD is characterized by an age-related degeneration of the retina. The root cause for this degeneration or why some peopl...
Eligibility Criteria
Inclusion
- Major
- \- At least one eye with geographic atrophy secondary to dry age-related macular degeneration (AMD)
- Major
Exclusion
- \- Medical condition, which may interfere with the progression of GA, prevent performance of study procedures, compliance with protocol, or continuous participation in the study
Key Trial Info
Start Date :
May 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03845582
Start Date
May 7 2019
End Date
June 30 2024
Last Update
November 3 2025
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Alkeus Site
Phoenix, Arizona, United States, 85053
2
Alkeus Site
Beverly Hills, California, United States, 90211
3
Alkeus Site
Lakewood, Colorado, United States, 80228
4
Alkeus Site
Clearwater, Florida, United States, 33761